The earnings call highlighted significant achievements, including record-breaking revenue and increased market share for HEPLISAV-B, along with positive updates in the vaccine pipeline and strategic financial decisions. However, there were challenges such as increased SG&A expenses and a reduction in cash reserves. Overall, the positive aspects significantly outweigh the negatives.

Company Guidance -

Q3 2025

During the Dynavax Technologies Second Quarter 2025 Financial Results Conference Call, the company provided several key metrics and updates on their performance and future guidance. Dynavax reported their highest-ever revenue quarter for HEPLISAV-B, with $92 million in Q2 net product revenue, marking a 31% increase year-over-year. Their market share in the U.S. adult hepatitis B vaccine market grew to 45%, up from 42% in the same quarter last year. The company revised its full-year 2025 HEPLISAV-B net product revenue guidance to a range of $315 million to $325 million, raising the lower end from $305 million. Dynavax also highlighted progress in their vaccine pipeline, including expected top-line results from a Phase I/II trial for a novel shingles program and advancements in pandemic influenza and Lyme disease vaccine programs. Additionally, the company completed a $200 million share repurchase program and maintained a robust financial profile with $614 million in cash, cash equivalents, and marketable securities. The guidance for adjusted EBITDA for the year remains at least $75 million, underscoring Dynavax's strong market position and strategic focus on long-term growth.

Record-Breaking HEPLISAV-B Revenue

Achieved $92 million in Q2 net product revenue for HEPLISAV-B, a 31% year-over-year increase, with a market share increase to 45% from 42% compared to the prior year.

Increased Full-Year Revenue Guidance

Updated full year 2025 HEPLISAV-B net product revenue guidance to $315 million to $325 million, raising the low end from $305 million.

Strong Financial Performance

Achieved GAAP net income of $19 million in Q2 2025, compared to $11 million in Q2 2024, with non-GAAP adjusted EBITDA improving to $37 million from $20 million year-over-year.

Vaccine Pipeline Progress

Reported progress in vaccine pipeline, including Phase I/II shingles vaccine trials and advancing pandemic influenza and Lyme disease programs.

Strategic Share Repurchase

Completed a $200 million share repurchase program, retiring over 16 million shares, contributing to a strong financial position.

Dynavax (DVAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DVAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.13 / -	0.12	―	―	―
Aug 07, 2025	2025 (Q2)	0.10 / 0.14	0.08	75.00% (+0.06)
May 06, 2025	2025 (Q1)	0.03 / -0.77	-0.07	-1000.00% (-0.70)
Feb 20, 2025	2024 (Q4)	0.04 / 0.05	0	―
Nov 07, 2024	2024 (Q3)	0.11 / 0.12	0.1	20.00% (+0.02)
Aug 06, 2024	2024 (Q2)	0.07 / 0.08	0.03	166.67% (+0.05)
May 08, 2024	2024 (Q1)	-0.02 / -0.07	-0.19	63.16% (+0.12)
Feb 22, 2024	2023 (Q4)	-0.01 / 0.00	0.45	―
Nov 02, 2023	2023 (Q3)	-0.04 / 0.10	0.43	-76.74% (-0.33)
Aug 03, 2023	2023 (Q2)	-0.09 / 0.03	0.87	-96.55% (-0.84)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DVAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$11.06	$10.33	-6.60%
May 06, 2025	$10.92	$9.72	-10.99%
Feb 20, 2025	$13.33	$13.33	0.00%
Nov 07, 2024	$12.02	$13.01	+8.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dynavax Technologies Corp. (DVAX) report earnings?

Dynavax Technologies Corp. (DVAX) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Dynavax Technologies Corp. (DVAX) earnings time?

Dynavax Technologies Corp. (DVAX) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DVAX EPS forecast?

DVAX EPS forecast for the fiscal quarter 2025 (Q3) is 0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing